Business Context and Reporting Period
Company: Qilian International Holding Group Limited (Note: Request metadata listed "BGM Group Ltd.", but the filing text identifies the registrant as Qilian International Holding Group Limited, trading as "QLI" on Nasdaq).
Reporting Period: Fiscal year ended September 30, 2020.
Business Overview: A Cayman Islands holding company operating primarily in China through a Variable Interest Entity (VIE) structure. The company develops, manufactures, and sells pharmaceutical products (oxytetracycline, licorice derivatives, heparin), traditional Chinese medicine derivatives (TCMD), sausage casings, and fertilizers.
Corporate Structure: Operations are conducted via contractual arrangements with Gansu Qilianshan Pharmaceutical Co., Ltd. (Gansu QLS) and its subsidiaries due to PRC restrictions on foreign ownership in certain pharmaceutical sectors.
Key Financial Metrics (Fiscal Year Ended Sept 30, 2020)
| Metric | 2020 | 2019 |
|---|---|---|
| Net Revenue | $50,033,200 | $46,096,684 |
| Gross Profit | $7,539,153 | $9,679,912 |
| Gross Margin | 15.1% | 21.0% |
| Net Income (Consolidated) | $4,940,441 | $5,908,479 |
| Net Income Attributable to Shareholders | $5,063,710 | $5,332,318 |
| EBITDA (Non-GAAP) | $7,153,814 | $8,353,749 |
| Cash and Cash Equivalents | $11,867,130 | $4,594,440 |
| Total Current Assets | $37,517,422 | $24,969,728 |
| Total Current Liabilities | $18,423,771 | $11,657,980 |
| Bank Loans (Current) | $7,349,375 | $4,903,128 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased by 9% ($3.9 million) driven by an 8% increase in Oxytetracycline/Licorice sales and a 9% increase in Heparin/Sausage casing sales. The Oxytetracycline increase was largely due to a production suspension in 2019 for facility maintenance, making 2020 volumes higher by comparison.
- Margin Compression: Gross margin declined significantly from 21.0% to 15.1%. This was primarily caused by a 4-8% increase in raw material costs due to COVID-19 supply chain disruptions and a 50% increase in the cost of pig intestines (used for heparin and sausage casings) due to African Swine Fever.
- Segment Performance: The Heparin and Sausage Casing segment turned from a 9.7% gross margin in 2019 to a negative 2.7% margin in 2020. While heparin sales increased due to pandemic demand, sausage casing sales dropped 2.3 million due to the swine fever impact on raw material supply and demand.
- SG&A Expenses: Selling, General, and Administrative expenses decreased by 22% ($0.8 million), primarily due to the absence of significant IPO-related professional fees incurred in 2019.
- Liquidity: Cash and cash equivalents more than doubled to $11.9 million, supported by a $5.1 million net cash inflow from operating activities and a $2.1 million inflow from financing activities (net bank loan proceeds).
Guidance, Outlook, Risks, and Unusual Items
- Capital Needs: Management estimates a need for at least $26 million to execute business plans, including expanding marketing for "Gan Di Xin" and increasing manufacturing capacity. The company intends to raise additional capital through equity or debt offerings.
- COVID-19 Impact: The pandemic caused raw material shortages and price increases. While operations resumed in February 2020, the company notes uncertainty regarding future global economic impacts and potential resurgences.
- Internal Control Weaknesses: The company identified material weaknesses in internal control over financial reporting as of September 30, 2020, specifically regarding the ability of in-house accounting professionals to generate financial statements compliant with SEC requirements. Remediation plans include recruiting personnel with U.S. GAAP expertise.
- Regulatory and Legal Risks:
- VIE Structure: Reliance on contractual arrangements with the VIE (Gansu QLS) creates risks if PRC authorities deem them non-compliant with foreign investment laws.
- PCAOB Inspection: Risks related to the inability of the PCAOB to inspect the company's auditor in China, which could impact continued listing on Nasdaq.
- Compliance: The company has not fully complied with PRC regulations regarding social insurance and housing fund contributions for all employees, though management believes penalties are unlikely.
- Customer Concentration: Revenue is concentrated among a few large customers. In 2020, the top three customers represented 18%, 11%, and 10% of sales, respectively. The company lacks long-term supply agreements with these key customers.
Investor Verification Checklist
- Internal Controls: Verify the progress of remediation efforts for the identified material weaknesses in financial reporting.
- Raw Material Costs: Monitor the stability of raw material prices (specifically pig intestines and licorice) and the company's ability to pass cost increases to customers.
- VIE Validity: Assess the ongoing legal opinion regarding the enforceability of the VIE agreements under evolving PRC laws.
- Capital Raising: Track the company's ability to secure the estimated $26 million in additional financing required for expansion.
- Customer Retention: Evaluate the stability of relationships with the top three customers who collectively account for nearly 40% of revenue.
- Regulatory Compliance: Confirm the status of social insurance and housing fund compliance to assess potential future liabilities.